Drugs / SKL27969
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05388435 | Sep 2022 → Mar 2024 | neoplasm | SK Life Science, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SKL27969 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05388435 ↗ |
| Route | Oral | “orally administered once daily” NCT05388435 ↗ |